• DOMA Perpetual Capital Management, holding about 7.5% of Pacira, urged investors to vote for its three board nominees at the June 9, 2026 annual meeting.
• DOMA cited persistent share-price declines, including -10% YTD, -9% over one year, -65% over five years, as evidence of board underperformance.
• DOMA argued management has overstated patent protection for EXPAREL, warning additional legal losses could accelerate generic entry and hit a product it says drives about 80% of revenue.
• The activist pressed the board to explore a potential sale, alleging directors are resisting strategic alternatives to protect their positions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacira Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605280918PR_NEWS_USPR_____FL70249) on May 28, 2026, and is solely responsible for the information contained therein.